Vitrolife AB (publ) (VTRLY)
| Market Cap | 1.32B -40.3% |
| Revenue (ttm) | 373.21M -4.7% |
| Net Income | -543.76M |
| EPS | -4.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 20.24 |
| Dividend | 0.07 (0.63%) |
| Ex-Dividend Date | May 2, 2025 |
| Volume | 130 |
| Average Volume | 1,068 |
| Open | 11.00 |
| Previous Close | 9.50 |
| Day's Range | 11.00 - 11.00 |
| 52-Week Range | 9.50 - 18.55 |
| Beta | 1.97 |
| RSI | 38.88 |
| Earnings Date | Mar 26, 2026 |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden. [Read more]
News
Vitrolife AB (publ) - Fourth quarter and full year report 2025
GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ -- Fourth quarter Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local curren...
Invitation to Vitrolife Group's presentation of the fourth quarter and full year report 2025
GOTHENBURG, Sweden, Jan. 20, 2026 /PRNewswire/ -- Vitrolife AB (publ) will publish its fourth quarter and full year report 2025 on Tuesday, 3 February 2026 at 08:00 am CET. A conference call for inves...
Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026
GOTHENBURG, Sweden , Oct. 29, 2025 /PRNewswire/ -- In accordance with the Nomination Committee Charter adopted at the Annual General Meeting 2025, the members who, together with the Chair of the Board...